Los Angeles Capital Management
HRTX icon

Los Angeles Capital Management’s Heron Therapeutics HRTX Stock Holding History

Los Angeles Capital Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$51.3K Sell
120,293
-122,710
-50% -$98.4K ﹤0.01% 1507
2026
Q1 		$194K Sell
243,003
-5,564
-2% -$6.45K ﹤0.01% 1152
2025
Q4 		$283K Buy
248,567
+2,154
+0.9% +$2.66K ﹤0.01% 1121
2025
Q3 		$310K Sell
246,413
-19,715
-7% -$31.3K ﹤0.01% 1110
2025
Q2 		$551K Buy
266,128
+198,325
+293% +$405K ﹤0.01% 829
2025
Q1 		$149K Buy
67,803
+150
+0.2% +$291 ﹤0.01% 1056
2024
Q4 		$104K Sell
67,653
-153,181
-69% -$248K ﹤0.01% 1085
2024
Q3 		$439K Sell
220,834
-18,065
-8% -$43.1K ﹤0.01% 897
2024
Q2 		$836K Sell
238,899
-254,365
-52% -$781K ﹤0.01% 713
2024
Q1 		$1.37M Sell
493,264
-21,113
-4% -$53.1K ﹤0.01% 591
2023
Q4 		$874K Buy
514,377
+171,250
+50% +$189K ﹤0.01% 719
2023
Q3 		$353K Buy
343,127
+3,653
+1% +$5.2K ﹤0.01% 917
2023
Q2 		$394K Sell
339,474
-366,203
-52% -$653K ﹤0.01% 929
2023
Q1 		$1.07M Buy
705,677
+538,024
+321% +$1.35M ﹤0.01% 649
2022
Q4 		$419K Sell
167,653
-5,400
-3% -$17.4K ﹤0.01% 937
2022
Q3 		$730K Buy
+173,053
New +$677K ﹤0.01% 805
2021
Q2 		– Sell
-15,940
Closed -$258K – 1602
2021
Q1 		$258K Sell
15,940
-9,710
-38% -$173K ﹤0.01% 1473
2020
Q4 		$543K Sell
25,650
-50
-0.2% -$869 ﹤0.01% 1177
2020
Q3 		$381K Buy
25,700
+1,230
+5% +$19.2K ﹤0.01% 1192
2020
Q2 		$360K Buy
24,470
+9,276
+61% +$152K ﹤0.01% 1232
2020
Q1 		$178K Buy
+15,194
New +$286K ﹤0.01% 1203
2019
Q2 		– Sell
-14,890
Closed -$364K – 1377
2019
Q1 		$364K Sell
14,890
-4,800
-24% -$126K ﹤0.01% 1158
2018
Q4 		$511K Buy
19,690
+11,640
+145% +$320K ﹤0.01% 958
2018
Q3 		$255K Buy
+8,050
New +$300K ﹤0.01% 1272

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Los Angeles Capital Management's HRTX Position: Q2 2026 in Review

Los Angeles Capital Management reduced its Heron Therapeutics (HRTX) stake by 50% in Q2 2026, selling an estimated $98.4K and leaving 120,293 shares worth $51.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1507.

Los Angeles Capital Management first reported a position in HRTX in Q3 2018 and has held it in 24 quarters since. The position peaked at $1.37M in Q1 2024. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • Los Angeles Capital Management held 120,293 shares of Heron Therapeutics worth $51.3K as of Q2 2026.
  • Los Angeles Capital Management sold 122,710 Heron Therapeutics shares in Q2 2026, an estimated $98.4K.
  • Heron Therapeutics made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #1507 holding.
  • Los Angeles Capital Management first reported a position in Heron Therapeutics in Q3 2018 and has held it in 24 quarters since.
  • Los Angeles Capital Management's Heron Therapeutics position peaked at $1.37M in Q1 2024.
  • 163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.